Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 3:59 pm Sale | 2022-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Polar Capital Holdings Plc | 2,071,242 2.300% | -2,928,758 (-58.58%) | Filing History |
| 2023-02-09 11:22 am Sale | 2022-12-30 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | The Vanguard Group | 5,313,679 5.950% | -469,754 (-8.12%) | Filing History |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | BlackRock Inc. BLK | 2,305,486 2.600% | -4,362,017 (-65.42%) | Filing History |
| 2022-02-14 2:01 pm Sale | 2021-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | BIOTECHNOLOGY VALUE FUND L P | 6,353,645 7.100% | -2,030,000 (-24.21%) | Filing History |
| 2022-02-14 1:38 pm Sale | 2021-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | EcoR1 Capital, LLC | 0 0.000% | -4,368,500 (Position Closed) | Filing History |
| 2022-02-14 10:41 am Purchase | 2021-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Polar Capital Holdings Plc | 5,000,000 5.600% | 5,000,000 (New Position) | Filing History |
| 2022-02-10 08:17 am Purchase | 2021-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | The Vanguard Group | 5,783,433 6.500% | 3,888,514 (+205.21%) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | BlackRock Inc. BLK | 6,667,503 7.500% | 5,754,043 (+629.92%) | Filing History |
| 2022-01-18 4:12 pm Sale | 2021-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Integrated Core Strategies (US) LLC | 743,271 0.800% | -4,319,036 (-85.32%) | Filing History |
| 2021-06-17 4:16 pm Purchase | 2021-06-10 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Integrated Core Strategies (US) LLC | 5,062,307 5.700% | 5,062,307 (New Position) | Filing History |
| 2021-02-19 5:10 pm Unchanged | 2021-02-17 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | BIOTECHNOLOGY VALUE FUND L P | 8,383,645 9.960% | 0 (Unchanged) | Filing History |
| 2021-02-16 4:30 pm Sale | 2021-02-11 | 13D | Infinity Pharmaceuticals, Inc. INFIQ | BIOTECHNOLOGY VALUE FUND L P | 8,383,645 13.100% | -2,343,323 (-21.85%) | Filing History |
| 2021-02-12 5:20 pm Purchase | 2020-12-31 | 13G | Infinity Pharmaceuticals, Inc. INFIQ | Opaleye Management Inc. | 3,171,800 4.940% | 171,400 (+5.71%) | Filing History |